Tetralogy of Fallot is an Uncommon Manifestation of Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome

Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare immunodeficiency disorder. We report three patients with WHIM syndrome who are affected by Tetralogy of Fallot (TOF). This observation suggests a possible increased risk of TOF in WHIM syndrome and that birth presentation of TOF and neutropenia should lead to suspect WHIM syndrome. Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare immunodeficiency disorder. We report three patients with WHIM syndrome who are affected by Tetralogy of Fallot (TOF). This observation suggests a possible increased risk of TOF in WHIM syndrome and that birth presentation of TOF and neutropenia should lead to suspect WHIM syndrome. Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare immunodeficiency disorder characterized by warts, hypogammaglobulinemia, infections, and abnormal retention of mature neutrophils in the bone marrow (myelokathexis).1Zuelzer W.W. “Myelokathexis”: a new form of chronic granulocytopenia. Report of a case.N Engl J Med. 1964; 270: 973-979Crossref PubMed Scopus (136) Google Scholar, 2Gorlin R.J. Gelb B. Diaz G.A. Lofsness K.G. Pittelkow M.R. Fenyk J.R.J. WHIM syndrome, an autosomal dominant disorder: clinical, haematological, and molecular studies.Am J Med Genet. 2000; 91: 368-376Crossref PubMed Scopus (165) Google Scholar This neutropenia, which is associated with a B and T lymphopenia and hypogammaglobulinemia, results in an increased risk for bacterial infections. Patients with WHIM syndrome present major and selective susceptibility to human papillomavirus that may manifest as cutaneous warts and genital dysplasia and cancer. The real prevalence of the disease is unknown but ∼40 cases have been reported.3Dotta L. Tassone L. Badolato R. Clinical and genetic features of warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome.Curr Mol Med. 2011; 11: 317-325Crossref PubMed Scopus (62) Google Scholar Autosomal dominant heterozygous mutations of the gene encoding the CXC chemokine receptor 4 (CXCR4) have been associated with the syndrome4Hernandez P.A. Gorlin R.J. Lukens J.N. Taniuchi S. Bohinjec J. Francois F. et al.Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease.Nat Genet. 2003; 34: 70-74Crossref PubMed Scopus (538) Google Scholar and lead to a gain of CXCR4 function.5Balabanian K. Lagane B. Pablos J.L. Laurent L. Planchenault T. Verola O. et al.WHIM syndrome with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12.Blood. 2004; 105: 2449-2457Crossref PubMed Scopus (241) Google Scholar, 6Lagane B. Chow K.Y. Balabanian K. Levoye A. Harriaque J. Planchenault T. et al.CXCR4 dimerization and beta-arrestin-mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome.Blood. 2008; 112: 34-44Crossref PubMed Scopus (131) Google Scholar CXCR4 is a G protein–coupled receptor with a unique ligand, CXCL12 (previously named SDF-1).7Diaz G.A. Gulino A.V. WHIM syndrome: a defect in CXCR4 signaling.Curr Allergy Asthma Rep. 2005; 5: 350-355Crossref PubMed Scopus (46) Google Scholar, 8Bachelerie F. CXCL12/CXCR4-axis dysfunctions: Markers of the rare immunodeficiency disorder WHIM syndrome.Dis Markers. 2010; 29: 189-198Crossref PubMed Google Scholar This signaling axis orchestrates leukocyte trafficking and is involved in the regulation of bone marrow homeostasis, hematopoiesis, and organogenesis.9Nagasawa T. A chemokine, SDF-1/PBSF, and its receptor, CXC chemokine receptor 4, as mediators of haematopoiesis.Int J Haematol. 2000; 72: 408-411PubMed Google Scholar, 10Cronshaw D.G. Nie Y. Waite J. Zou Y.-R. An essential role of the cytoplasmic tail of CXCR4 in G-protein signaling and organogenesis.PLoS One. 2010; 5: e15397Crossref PubMed Scopus (14) Google Scholar, 11Kawai T. Choi U. Cardwell L. DeRavin S.S. Naumann N. Whiting-Theobald N.L. et al.WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4.Blood. 2007; 109: 78-84Crossref PubMed Scopus (74) Google Scholar Notably, besides hematopoietic and central nervous system defects, mice deficient for CXCR4 or CXCL12 exhibit cardiac defects, indicating a role for this axis in ventricular septum formation.12Zou Y.R. Kottmann A.H. Kuroda M. Taniuchi I. Littman D.R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development.Nature. 1998; 393: 595-599Crossref PubMed Scopus (2126) Google Scholar, 13Nagasawa T. Nakajima T. Tachibana K. Iizasa H. Bleul C.C. Yoshie O. et al.Molecular cloning and characterization of a murine pre-B-cell growth-stimulating factor/stromal cell-derived factor 1 receptor, a murine homolog of the human immunodeficiency virus 1 entry coreceptor fusin.Proc Natl Acad Sci U S A. 1996; 93: 14726-14729Crossref PubMed Scopus (268) Google Scholar Tetralogy of Fallot (TOF) is a congenital heart disease characterized by: (1) pulmonary outflow tract obstruction; (2) ventricular septal defect; (3) overriding aortic root; and (4) right ventricular hypertrophy. The first 3 features are the result of abnormalities occurring during embryogenesis, and the fourth one is the consequence of the obstruction to pulmonary blood flow. The etiology is multifactorial. To date, some genetic alterations, the most frequent being represented by microdeletions of chromosome 22, have been associated with TOF but pathogenesis still remains unclear. The incidence is of 3 of every 10 000 live births, which represents approximately 10% of all congenital defects.14Apitz C. Webb G.D. Redington A.N. Tetralogy of Fallot.Lancet. 2009; 374: 1462-1471Abstract Full Text Full Text PDF PubMed Scopus (357) Google Scholar, 15Starr J.P. Tetralogy of Fallot: yesterday and today.World J Surg. 2010; 34: 658-668Crossref PubMed Scopus (97) Google Scholar, 16Piran S. Bassett A.S. Grewal J. Swaby J.A. Morel C. Oechslin E.N. et al.Patterns of cardiac and extracardiac anomalies in adults with tetralogy of Fallot.Am Heart J. 2011; 161: 131-137Abstract Full Text Full Text PDF PubMed Scopus (24) Google Scholar We report the cases of 3 patients with WHIM syndrome who are affected by TOF (Figure). Taking into consideration the relatively poor prevalence of the two disorders, in the present report we show that patients with WHIM syndrome display an increased risk to develop TOF. The first patient is a 19-year-old man with a history of WHIM syndrome identified at age 2.5 years, manifesting as severe neutropenia and recurrent pneumonias, resulting in bronchiectases (Table). There was no evidence of hypogammaglobulinemia and warts. The bone marrow analysis showed myeloid hypercellularity with the presence of mature neutrophils. These hematologic and clinical findings led to the suspicion of WHIM syndrome and thereby to CXCR4 gene sequencing that revealed S338X mutation. The congenital heart disease was suspected at birth and was characterized by the anatomic variant of TOF associated with pulmonary atresia and with anomalies in branch pulmonary arteries. Of note, the patient presented with agenesis of the left-hand fingers with homolateral hypoplasia of the radius. The patient has been maintained on daily subcutaneously administered granulocyte-colony stimulating factor therapy since 2 years of age.TableFeatures of WHIM syndrome in reported patientsFeaturePatient 1Patient 2Patient 3Mutation (CXCR4)S338XR334XS338XAge at molecular diagnosis19 y5 yBirth (neutropenia and affected father)Clinical manifestations at onsetTOFTOFTOF; neutropeniaNeutropenia (age at onset)+ (2.5 y)+ (2 y)+ (20 d)Myelokathexis+++Hypogammaglobulinemia (age at onset)−+ (5 y)+ Not really assessable as early IVIG at the onsetRecurrent infectionsPneumoniaPneumonia−Warts−+∗One episode without relapse.−Pulmonary outflow obstructionPulmonary valve agenesisPulmonary infundibular stenosisPulmonary infundibular stenosisOverriding aorta+++Ventricular septal defect+++Right ventricular hypertrophy+−−Age at surgical correction1 y2 y2.5 moMedical treatmentG-CSF; antibiotic prophylaxisG-CSF; antibiotic prophylaxisIVIGG-CSF, Granulocyte-colony stimulating factor; IVIG, Intravenous immunoglobulins.∗ One episode without relapse. Open table in a new tab G-CSF, Granulocyte-colony stimulating factor; IVIG, Intravenous immunoglobulins. In the second case, the patient had TOF associated with the presence of patent ductus arteriosus documented at birth; the heart disease was surgically corrected at the age of 2 years (Table). This patient is a 15-year-old girl who has had recurrent respiratory infections since early childhood. Severe neutropenia was discovered at age of 2 years, and on that occasion, an analysis of the bone marrow revealed myelokathexis with mature neutrophils presenting morphologic abnormalities consistent with apoptosis. Granulocyte-colony stimulating factor therapy was started at 5 years of age to maintain circulating neutrophil count in the normal range. Because of the occurrence of repeated pneumonia episodes, she has been maintained on antibiotic prophylaxis. In the following years, the observation of hypogammaglobulinemia suggested WHIM syndrome and genetic confirmation of the diagnosis was obtained at age 5 by detection of the R334X mutation in the CXCR4 gene. In the following years, the patient has developed a plantar wart. The third patient is 7 years old and presented shortly after birth with a heart murmur that led to the discovery of a TOF characterized by ventricular septal defect, overriding aorta, and pulmonary infundibular stenosis. The congenital heart disease was surgically corrected in the first months of life. Neutropenia, lymphopenia, and hypogammaglobulinemia were present since infancy, and the analysis of bone marrow showed myelokathexis. Three other family members have had neutropenia and recurrent infections, but none of them had a congenital heart defect. The genetic analysis of CXCR4 revealed the same mutation (S338X) in the 4 subjects. The child underwent treatment with intravenous immunoglobulins, obtaining a satisfactory control of infectious episodes. Although TOF is the most common form of cyanotic congenital heart disease, its occurrence in 3 unrelated patients with WHIM syndrome is much higher than expected; the normal occurrence in the general population is 3 of every 10 000 live births. Because of the low number of patients whom we have observed, we cannot draw a correlation between the development of the heart defect with a specific mutation. The detection of the same mutation (S338X) in a family with 4 members affected by WHIM syndrome with only 1 showing TOF rules out the hypothesis that the heterozygous gain-of-function mutation of CXCR4 directly leads to the development of the cardiac defect. Instead, our observations suggest that the WHIM syndrome–associated CXCR4 truncating mutation might increase the risk that this combination of cardiac defects may develop during the formation of the fetal heart. Beyond a role for CXCL12 and CXCR4 in heart, nervous system, and blood vessel development,17Nagasawa T. Role of chemokine SDF-1/PBSF and its receptor CXCR4 in blood vessel development.Ann N Y Acad Sci. 2001; 947: 112-115Crossref PubMed Scopus (24) Google Scholar studies show that CXCR7, the recently described second receptor for CXCL12,18Balabanian K. Lagane B. Infantino S. Chow K.Y. Harriague J. Moepps B. et al.The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes.J Biol Chem. 2005; 280: 35760-35766Crossref PubMed Scopus (839) Google Scholar, 19Burns J.M. Summers B.C. Wang Y. Melikian A. Berahovich R. Miao Z. et al.A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development.J Exp Med. 2006; 203: 2201-2213Crossref PubMed Scopus (1044) Google Scholar has also a role in fetal endothelial biology and heart development—in particular, ventricular septum and heart valve development.20Sierro F. Biben C. Martínez-Muñoz L. Mellado M. Ransohoff R.M. Li M. et al.Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7.Proc Natl Acad Sci U S A. 2007; 104: 14759-14764Crossref PubMed Scopus (486) Google Scholar, 21Dai X. Tan Y. Cai S. Xiong X. Wang L. Ye Q. et al.The role of CXCR7 on the adhesion, proliferation and angiogenesis of endothelial progenitor cells.J Cell Mol Med. 2011; 15: 1299-1309Crossref PubMed Scopus (84) Google Scholar Its germline deletion results in perinatal lethality, and its mutation affects semilunar valve development, contributing to aortic and pulmonary valve stenosis and, in some cases, septal defects.22Yu S. Crawford D. Tsuchihashi T. Behrens T.W. Srivastava D. The chemokine receptor CXCR7 functions to regulate cardiac valve remodeling.Dev Dyn. 2011; 240: 384-393Crossref PubMed Scopus (59) Google Scholar Recent findings support the view that CXCR7 modulates CXCR4 function by acting as a scavenger for CXCL1223Naumann U. Cameroni E. Pruenster M. Mahabaleshwar H. Raz E. Zerwes H.G. et al.CXCR7 functions as a scavenger for CXCL12 and CXCL11.PLoS One. 2010; 5: e9175Crossref PubMed Scopus (354) Google Scholar and forming heterodimers with CXCR4.20Sierro F. Biben C. Martínez-Muñoz L. Mellado M. Ransohoff R.M. Li M. et al.Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7.Proc Natl Acad Sci U S A. 2007; 104: 14759-14764Crossref PubMed Scopus (486) Google Scholar, 24Levoye A. Balabanian K. Baleux F. Bachelerie F. Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling.Blood. 2009; 113: 6085-6093Crossref PubMed Scopus (483) Google Scholar, 25Decaillot F.M. Kazmi M.A. Lin Y. Ray-Saha S. Sakmar T.P. Sachdev P. CXCR7/CXCR4 heterodimer constitutively recruits {beta}-arrestin to enhance cell migration.J Biol Chem. 2011; 286: 32188-32197Crossref PubMed Scopus (274) Google Scholar In vitro studies on endothelial progenitor cell function show a role for both CXCR4 and CXCR7 in regulating the response of the cells to CXCL12 and, thus, angiogenesis.21Dai X. Tan Y. Cai S. Xiong X. Wang L. Ye Q. et al.The role of CXCR7 on the adhesion, proliferation and angiogenesis of endothelial progenitor cells.J Cell Mol Med. 2011; 15: 1299-1309Crossref PubMed Scopus (84) Google Scholar This suggests that interactions between the 2 chemokine receptors may be required for proper valve morphogenesis. Our observations demonstrate that TOF can be a presenting manifestation of WHIM syndrome and that this rare inherited disease should be suspected in children with a congenital heart defect and neutropenia. The recognition of this manifestation of WHIM syndrome might help to prevent the diagnostic delay in the identification of this rare genetic disease. A prompt diagnosis should facilitate the management of leucopenia, which might include in the future CXCR4-targeted therapy as supported by 2 recent studies indicating that the specific CXCR4 antagonist plerixafor may be effective in restoring the cellular blood counts to normal.26McDermott D.H. Liu Q. Ulrick J. Kwatemaa N. O’Brien S.A. Penzak S.R. et al.The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.Blood. 2011; 118: 4957-4962Crossref PubMed Scopus (110) Google Scholar, 27Dale D.C. Bolyard A.A. Kelley M.L. et al.The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.Blood. 2011; 118: 4963-4966Crossref PubMed Scopus (79) Google Scholar We are grateful to Virginia Gulino for critical discussion.